 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| It has been a couple of years since we last covered BICX on its epic run up to .33. Well the recent news is huge and a game changer for the team at BICX! We will have much more to read about tomorrow, but read the PR below and add BICX to your watch list ASAP. |
|
 Hot Stock to Watch |
Company: BioCorRx Inc. (Pink Sheets: BICX)
|
Last:
Price: 0.0205
Change (%): - 0.0035 (14.58)
Volume: 137,062 |
 |
Alpine Creek and BioCorRx Announce Major Investment Into BioCorRx
SANTA ANA, CA--(Marketwired - Jun 20, 2016) - Alpine Creek Capital Partners ("Alpine Creek") and BioCorRx, Inc. (OTC PINK: BICX) ("BioCorRx" or "the Company") are pleased to announce an investment by Alpine Creek in the Company. The Company specializes in solutions for alcohol and opioid addiction treatment using its proprietary, non-addictive medication-assisted treatment (MAT) program called the BioCorRx® Recovery Program. The Company has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of an FDA-approved medicine, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant can significantly reduce cravings for alcohol or opioids for several months, depending on individual metabolism rates. In addition to the implant formulation, and perhaps more important, is the Company's comprehensive counseling program that was developed by addiction experts specific to individuals undergoing treatment with any form of sustained-release naltrexone.
Travis Mullen, Managing Partner of Alpine Creek Capital Partners, said, "We couldn't be more excited about our investment in BioCorRx and the cutting edge program they have in place. The BioCorRx® Recovery Program which includes this naltrexone delivery system coupled with the tangible counseling program is literally saving lives and we look forward to arming as many families as possible with this amazing tool for their battle against alcohol or opioid addiction."
The initial investment in the Company is 2,500,000 dollars with an additional 2,500,000 dollars expected within six months at the option of Alpine Creek. Details of the transaction can be found in the Company's filings with the Securities and Exchange Commission. In the coming weeks and months, the Company will announce its plans and initiatives for using the capital received from Alpine Creek.
Brady Granier, CEO of BioCorRx, Inc., stated, "This is the single largest investment made in our company in its five plus years of existence. Since last year, Alpine has been a valued and trusted financial partner of BioCorRx and this transaction is a testament to the hard work that has been done by everyone in our company to create a product that we believe has great potential to combat this opioid epidemic, as well as the much larger alcoholism problem destroying families across the world. Our program and service model has evolved over the years into something we believe is truly unique and effective in battling addiction. With this significant partnership with Alpine, we will be able to start taking advantage of initiatives we have been dreaming about for years. The folks at Alpine are not your average investors. They really care about what we are doing and the impact it can make and they are also rolling up their sleeves and getting in the trenches along-side us to beat addiction."
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. Small Cap Voice received 500 dollars from the company on 7-7-16 for a one day email campaign. |
About Penny Stocks |
|
|
